Drug Profile

Allopurinol - ACE Pharmaceuticals

Alternative Names: ACEPURIN; Allokid^®; Allopurinol sodium - ACE Pharmaceuticals

Latest Information Update: 22 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ace Pharmaceuticals
Class Antigouts; Purines; Pyrazoles; Pyrimidinones; Skin disorder therapies; Uricosurics
Mechanism of Action Xanthine oxidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Asphyxia
New Molecular Entity No

Highest Development Phases

Phase III Asphyxia

Most Recent Events

22 Apr 2022 Allopurinol is still in phase III trials for Asphyxia in Portugal
01 Jan 2020 Ace Pharmaceuticals initiates a phase III CRUCIAL trial for Asphyxia (In neonates) in Netherlands (IV, Infusion) (NCT04217421)
09 Nov 2018 Phase-III clinical trials in Asphyxia (In neonates) in Switzerland (IV) (EudraCT2016-000222-19)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com